



Epigenetics of Pancreatic Cancer

Guest Editors:

Dr. Martin E. Fernandez-Zapico

Schulze Center for Novel Therapeutics, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA

Dr. Christopher Pin

Division Head and Scientist, Genetics and Development, Children's Health Research Institute Associate Professor, Depts. of Paediatrics, Physiology and Pharmacology, and Oncology Schulich School of Medicine and Dentistry, University of Western Ontario

Deadline for manuscript submissions:

closed (15 May 2018)

Message from the Guest Editors

Dear Colleagues,

This Special Issue focuses on the role of epigenetics in pancreatic cancer, a dismal disease predicted to be second cause of cancer death by 2030. This aggressive and rapidly-disseminated epithelial neoplasm is highly resistant to conventional chemotherapeutic and radiation-based treatments. The past several decades of pancreatic cancer research have yielded a tremendous amount of knowledge about the genetics of tumor cells; however, this knowledge has not translated into significant clinical advances in treatment and prevention. These genetic-based drivers of pancreatic cancer have been well studied, but they do not account for all of the phenotypic and molecular alterations demonstrated by tumor cells. Pancreatic cancer initiation and progression is the result of a heterogeneous and dynamic combination of both genetic and epigenetic mechanisms. With the identification of epigenetic alterations seen in early pancreatic preneoplastic lesions through the development of pancreatic cancer, there implies an inherent complexity in epigenetic changes that occurs in parallel to genetic changes. This Special Issue will discuss on the present knowledge in field pancreatic cancer epigenetics.

Dr. Martin E. Fernandez-Zapico

Dr. Christopher Pin

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at
Mount Sinai, Hess Center for
Science and Medicine, New York,
NY 10029, USA

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [ESCI \(Web of Science\)](#), [PMC](#), [PubMed](#), [Embase](#), [PubAg](#), [CAPlus / SciFinder](#), and [other databases](#).

Journal Rank: CiteScore - Q2 (*Biochemistry, Genetics and Molecular Biology (miscellaneous)*)

Contact Us

Epigenomes Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/epigenomes
epigenomes@mdpi.com
[X@Epigenomes](#)